Mercury Pharmaceuticals

We are de-risking biomedical innovations, while turning biomedical knowledge into social and economic value.

Stay Informed!

Neuroticism and adversity dominate depression and anxiety risk in UK Biobank study

25

Jun 2026

Neuroticism and adversity dominate depression and anxiety risk in UK Biobank study

In a UK Biobank study of 87,648 adults followed for 13.7 years, psychosocial factors accounted for the largest estimated population burden of depression and anxiety in both women and men. Neuroticism symptoms, childhood and adult adversity, obesity, chronic inflammation, and some reproductive factors in women were linked to incident mental health outcomes, although the PAF estimates remain theoretical and not proof of causality.

Gut microbes emerge as potential players in estrogen-driven cancers

25

Jun 2026

Gut microbes emerge as potential players in estrogen-driven cancers

A new review maps how the endocrine-microbiome axis expands the estrobolome concept, showing that gut microbes may alter estrogen recycling, produce hormone-like metabolites, and shape inflammation and tissue environments in hormone-driven cancers. Human evidence remains mostly associative, so the authors call for causal models, longitudinal multi-omics, multi-kingdom profiling, and sex-stratified studies before microbiome-guided cancer strategies enter routine care.

Rare Ebola strain may spread beyond Congo, study warns

25

Jun 2026

Rare Ebola strain may spread beyond Congo, study warns

A rare strain of Ebola that began spreading undetected in eastern Democratic Republic of Congo (DRC) in early April 2026 has now confirmed transmission in Uganda and is potentially on course to reach South Sudan, according to a new modelling study from the World Health Organization (WHO) published in The Lancet Infectious Diseases journal.

MERCURY trials

Clinical trials are very important as it allow us to evaluate the effectiveness of new drugs, new devices, preventative strategies or treatment strategies. It also enables us to discover better ways for patients' care.
- Learn more

Cancer

Our mission remains constant as we endeavor to deliver novel medicines to patients with cancer, treating solid tumors with high unmet medical needs in well-defined patient populations that are currently not well supported.
- Learn more

Neuroscience

Whether you're looking to manufacture toxicology batches or cGMP material for clinical trials, we can help you expedite molecules to clinic with full transparency.
- Learn more

Mercury Pharmaceuticals

Why Us?

Strong experience in academic research and technology transfer makes us understand your goals and motivations as a technology originator.
Our experience in drug development from discovery to clinical and commercial stages makes us an insider player within the biopharmaceutical industry.
Smart approach to project management that helps speed up development stages and decision making.
Availability of own investment up to 2m€ per project allows us to reach the next value milestone.